A Tale of Two Anti-Ebola Drugs

YANZHONG HUANG | June 16, 2017

article image
Since April, cases of Ebola virus disease (EVD) have been reported in the Democratic Republic of Congo. As of June 6, there were eight probable and confirmed cases, which were associated with four deaths. Thanks to the rapid and effective response coordinated by the World Health Organization (WHO) and its partners, the outbreak appears to have been brought under control.

Spotlight

Cempra Pharmaceuticals

Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.

OTHER ARTICLES

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | March 6, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 6, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 6, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | March 6, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Spotlight

Cempra Pharmaceuticals

Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.

Events